PFS boost with nivolumab–chemotherapy for advanced gastric, gastro-oesophageal cancer

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 28 / Springer Healthcare

PFS boost with nivolumab–chemotherapy for advanced gastric, gastro-oesophageal cancer

Oncology Gastrointestinal Cancer Cancer Immunotherapy ESMO-2020

Description

Narikazu Boku gives an overview of the ATTRACTION-4 data demonstrating improved outcomes with the addition of nivolumab to chemotherapy in the treatment-naïve, advanced or recurrent gastric or gastro-oesophageal junction cancer setting.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.